PT2983647T - Administração de aine e composições, métodos e sistemas relacionados - Google Patents
Administração de aine e composições, métodos e sistemas relacionadosInfo
- Publication number
- PT2983647T PT2983647T PT147231229T PT14723122T PT2983647T PT 2983647 T PT2983647 T PT 2983647T PT 147231229 T PT147231229 T PT 147231229T PT 14723122 T PT14723122 T PT 14723122T PT 2983647 T PT2983647 T PT 2983647T
- Authority
- PT
- Portugal
- Prior art keywords
- systems
- methods
- related compositions
- nsaid administration
- nsaid
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361811619P | 2013-04-12 | 2013-04-12 | |
US201361845240P | 2013-07-11 | 2013-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
PT2983647T true PT2983647T (pt) | 2020-11-09 |
Family
ID=50687535
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PT147231229T PT2983647T (pt) | 2013-04-12 | 2014-04-11 | Administração de aine e composições, métodos e sistemas relacionados |
Country Status (15)
Country | Link |
---|---|
US (2) | US20140308350A1 (pt) |
EP (1) | EP2983647B1 (pt) |
JP (1) | JP6433980B2 (pt) |
KR (1) | KR102190173B1 (pt) |
CN (1) | CN105324109A (pt) |
AU (1) | AU2014252219B2 (pt) |
CA (1) | CA2908525C (pt) |
EA (1) | EA032705B1 (pt) |
ES (1) | ES2829285T3 (pt) |
HK (1) | HK1213810A1 (pt) |
MX (1) | MX2015014307A (pt) |
NZ (1) | NZ713440A (pt) |
PL (1) | PL2983647T3 (pt) |
PT (1) | PT2983647T (pt) |
WO (1) | WO2014167533A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
DK3546464T3 (da) | 2014-05-12 | 2020-07-27 | Alfasigma Spa | Fremstilling og anvendelse af den krystallinske form tau af rifaximin solvateret med degme |
CN107550908A (zh) * | 2016-06-30 | 2018-01-09 | 康普药业股份有限公司 | 一种治疗下肠道溃疡的药物组合物 |
US20190336511A1 (en) * | 2018-05-02 | 2019-11-07 | Georgiy Brusovanik | Treatment for Inflammation and Pain with Reduced Gastro-Intestinal Side Effects Combining Methylprednisolone, Paracetamol, and Lansoprazole |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IT1154655B (it) | 1980-05-22 | 1987-01-21 | Alfa Farmaceutici Spa | Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica |
IT1199374B (it) | 1984-05-15 | 1988-12-30 | Alfa Farmaceutici Spa | Processo per la preparazione di pirido-imidazo-rifamicine |
ITMI20032144A1 (it) | 2003-11-07 | 2005-05-08 | Alfa Wassermann Spa | Forme polimorfe di rifaximina, processi per ottenerle e |
US20050249806A1 (en) * | 2004-02-10 | 2005-11-10 | Santarus, Inc. | Combination of proton pump inhibitor, buffering agent, and nonsteroidal anti-inflammatory drug |
US8003118B2 (en) * | 2005-03-02 | 2011-08-23 | Kodsi Robert E | Use of rifaximin for the prevention of aspiration pneumonia and/or sepsis |
PT1698630E (pt) | 2005-03-03 | 2014-09-15 | Alfa Wassermann Spa | Novas formas polimorfas de rifaximina, processos para a sua produção e a sua utilização nas preparações medicinais |
ITBO20050123A1 (it) * | 2005-03-07 | 2005-06-06 | Alfa Wassermann Spa | Formulazioni farmaceutiche gastroresistenti contenenti rifaximina |
ITMI20061692A1 (it) * | 2006-09-05 | 2008-03-06 | Alfa Wassermann Spa | Uso di polioli per ottenere forme polimorfe stabili di rifaximina |
WO2008035109A1 (en) | 2006-09-22 | 2008-03-27 | Cipla Limited | Rifaximin |
ITMI20071241A1 (it) | 2007-06-20 | 2008-12-21 | Solmag S P A | Processo per la preparazione di rifaximina amorfa e rifaximina amorfa cosi' ottenuta |
US7709634B2 (en) | 2007-09-20 | 2010-05-04 | Apotex Pharmachem Inc. | Amorphous form of rifaximin and processes for its preparation |
US8486956B2 (en) | 2008-02-25 | 2013-07-16 | Salix Pharmaceuticals, Ltd | Forms of rifaximin and uses thereof |
CN102015725B (zh) | 2008-02-25 | 2014-10-22 | 萨利克斯药品有限公司 | 利福昔明的多种形式及其用途 |
PL2252148T3 (pl) * | 2008-02-26 | 2019-09-30 | Salix Pharmaceuticals, Ltd. | Sposoby leczenia zespołu jelita drażliwego |
KR20130086338A (ko) | 2010-06-03 | 2013-08-01 | 샐릭스 파마슈티컬스 리미티드 | 리팍시민의 신규한 형태들 및 이들의 용도 |
EP2582707A4 (en) | 2010-06-16 | 2014-01-08 | Apotex Pharmachem Inc | POLYMORPHIC FORMS OF RIFAXIMINE |
IT1403847B1 (it) * | 2010-09-22 | 2013-11-08 | Alfa Wassermann Spa | Composizioni farmaceutiche comprendenti rifaximina e loro uso. |
EP2705042A1 (en) | 2011-05-02 | 2014-03-12 | Ranbaxy Laboratories Limited | Rifaximin dimethylformamide solvate |
WO2012155981A1 (en) | 2011-05-19 | 2012-11-22 | Friulchem Spa | New process for the synthesis of rifaximin and a new pseudo-crystalline form of rifaximin obtained thereby |
ITMI20110890A1 (it) | 2011-05-19 | 2012-11-20 | A M S A Anonima Materie Sint & Affini S P A | Polimorfo di rifaximina e processo per la sua preparazione |
WO2013112809A2 (en) * | 2012-01-25 | 2013-08-01 | Salix Pharmaceuticals, Ltd | Rifaximin derivative and uses thereof |
-
2014
- 2014-04-11 EP EP14723122.9A patent/EP2983647B1/en active Active
- 2014-04-11 CA CA2908525A patent/CA2908525C/en active Active
- 2014-04-11 NZ NZ713440A patent/NZ713440A/en not_active IP Right Cessation
- 2014-04-11 JP JP2016507100A patent/JP6433980B2/ja active Active
- 2014-04-11 WO PCT/IB2014/060640 patent/WO2014167533A1/en active Application Filing
- 2014-04-11 KR KR1020157032383A patent/KR102190173B1/ko active IP Right Grant
- 2014-04-11 AU AU2014252219A patent/AU2014252219B2/en active Active
- 2014-04-11 EA EA201591899A patent/EA032705B1/ru not_active IP Right Cessation
- 2014-04-11 CN CN201480033480.XA patent/CN105324109A/zh active Pending
- 2014-04-11 PL PL14723122T patent/PL2983647T3/pl unknown
- 2014-04-11 MX MX2015014307A patent/MX2015014307A/es active IP Right Grant
- 2014-04-11 US US14/251,516 patent/US20140308350A1/en not_active Abandoned
- 2014-04-11 ES ES14723122T patent/ES2829285T3/es active Active
- 2014-04-11 PT PT147231229T patent/PT2983647T/pt unknown
-
2016
- 2016-02-19 HK HK16101902.7A patent/HK1213810A1/zh unknown
-
2019
- 2019-06-28 US US16/457,814 patent/US20190388411A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2983647B1 (en) | 2020-09-09 |
CN105324109A (zh) | 2016-02-10 |
US20190388411A1 (en) | 2019-12-26 |
JP6433980B2 (ja) | 2018-12-05 |
EA201591899A1 (ru) | 2016-03-31 |
KR102190173B1 (ko) | 2020-12-14 |
PL2983647T3 (pl) | 2021-01-25 |
CA2908525A1 (en) | 2014-10-16 |
US20140308350A1 (en) | 2014-10-16 |
NZ713440A (en) | 2019-02-22 |
ES2829285T3 (es) | 2021-05-31 |
JP2016520556A (ja) | 2016-07-14 |
HK1213810A1 (zh) | 2016-07-15 |
KR20150140390A (ko) | 2015-12-15 |
EA032705B1 (ru) | 2019-07-31 |
AU2014252219A1 (en) | 2015-10-29 |
CA2908525C (en) | 2021-04-06 |
MX2015014307A (es) | 2015-12-08 |
WO2014167533A1 (en) | 2014-10-16 |
EP2983647A1 (en) | 2016-02-17 |
AU2014252219B2 (en) | 2018-11-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL267681A (en) | Selective grp94 inhibitors and their uses | |
HK1223645A1 (zh) | 用於序列操縱的優化的 雙切口酶系統、方法以及組合物 | |
IL246116B (en) | crispr-cas systems and their uses | |
EP2967817A4 (en) | IMPLANT INTRODUCTION DEVICES, SYSTEMS AND METHODS | |
EP2968304A4 (en) | 4-PHENYLPIPERIDINES, PREPARATION THEREOF AND USE THEREOF | |
EP2992097A4 (en) | Compositions and methods | |
EP2951283A4 (en) | Compositions and methods | |
EP3071295A4 (en) | Anti-infective methods, compositions, and devices | |
EP2968303A4 (en) | OCTAHYDROCYCLOPENTAPYROLE AND THEIR PREPARATION AND USE | |
EP3030974A4 (en) | Content delivery methods and systems | |
EP2999471A4 (en) | Systems, methods, and compositions for cross-linking | |
EP3057496A4 (en) | INTRAVASCULAR DEVICES, SYSTEMS AND METHODS | |
GB201314312D0 (en) | Composition and delivery system | |
HK1222563A1 (zh) | 藥物組合物、製備及其用途 | |
EP2967647A4 (en) | SURGICAL DEVICES, SYSTEMS AND CORRESPONDING METHODS | |
IL245445A0 (en) | Devices, kits and methods for osmotic administration of drugs | |
IL242795B (en) | Preparations, methods and devices for dialysis | |
EP3012292A4 (en) | TREATMENT ADJUVANT, AND COMPOSITION | |
HK1213800A1 (zh) | 類毒素、組合物及相關方法 | |
EP3065712A4 (en) | Microparticles, methods for their preparation and use | |
EP3049444A4 (en) | Systems, methods, and compositions for viral-associated tumors | |
HK1213810A1 (zh) | 施用和相關的組合物、方法和系統 | |
IL250844A0 (en) | Medical nanoparticles and related preparations, methods and systems | |
HK1213917A1 (zh) | 類霉素、組合物及相關方法 | |
HK1214862A1 (zh) | 無細胞生物碎片組合物及其相關系統,裝置和方法 |